CN112533942A - 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 - Google Patents

嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 Download PDF

Info

Publication number
CN112533942A
CN112533942A CN201980044894.5A CN201980044894A CN112533942A CN 112533942 A CN112533942 A CN 112533942A CN 201980044894 A CN201980044894 A CN 201980044894A CN 112533942 A CN112533942 A CN 112533942A
Authority
CN
China
Prior art keywords
cell
car
cells
cytokine
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980044894.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·库珀
J·F·迪珀西奥
A·卡特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN112533942A publication Critical patent/CN112533942A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980044894.5A 2018-06-01 2019-05-31 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 Pending CN112533942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679597P 2018-06-01 2018-06-01
US62/679597 2018-06-01
PCT/US2019/034981 WO2019232425A1 (en) 2018-06-01 2019-05-31 Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy

Publications (1)

Publication Number Publication Date
CN112533942A true CN112533942A (zh) 2021-03-19

Family

ID=68696762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044894.5A Pending CN112533942A (zh) 2018-06-01 2019-05-31 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制

Country Status (5)

Country Link
US (2) US20200054675A1 (enExample)
EP (1) EP3802578A4 (enExample)
JP (1) JP2021525530A (enExample)
CN (1) CN112533942A (enExample)
WO (1) WO2019232425A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735558A (zh) * 2018-12-12 2019-05-10 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN114410686A (zh) * 2021-12-24 2022-04-29 武汉大学 一种工程化外泌体原位纳米疫苗及其制备方法和应用
CN116102662A (zh) * 2022-10-10 2023-05-12 武汉波睿达生物科技有限公司 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用
CN116240173A (zh) * 2023-02-02 2023-06-09 西安电子科技大学 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用
CN117186202A (zh) * 2023-11-08 2023-12-08 北京大学第三医院（北京大学第三临床医学院） 一种新细胞因子csbf及其在干眼治疗中的应用
CN117866110A (zh) * 2023-12-27 2024-04-12 广东唯泰生物科技有限公司 一种靶向flt-3的第四代嵌合抗原受体及其应用
CN119345372A (zh) * 2024-10-28 2025-01-24 北京大学人民医院 Cd132在治疗aml中的应用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494132A4 (en) 2016-08-03 2020-03-18 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
US20200368285A1 (en) 2017-08-07 2020-11-26 The Regents Of The University Of California Platform for generating safe cell therapeutics
US20200040056A1 (en) * 2018-05-31 2020-02-06 Washington University Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
KR20210016431A (ko) * 2018-05-31 2021-02-15 워싱턴 유니버시티 암 치료용 키메라 항원 수용체 t 세포 (car-t)
JP2021525530A (ja) 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制
CN113518785A (zh) 2019-03-01 2021-10-19 艾洛基治疗公司 携带pd-1胞外域的嵌合细胞因子受体
US20230036569A1 (en) * 2019-12-17 2023-02-02 The General Hospital Corporation Engineered immune cells with reduced toxicity and uses thereof
EP3845646A1 (en) * 2019-12-30 2021-07-07 Secarna Pharmaceuticals GmbH & Co. KG Modified antisense oligonucleotide for inhibition of foxp3 expression
EP4110805A1 (en) * 2020-02-24 2023-01-04 Allogene Therapeutics, Inc. Bcma car-t cells with enhanced activities
CA3173490A1 (en) * 2020-04-06 2021-10-14 Biliang HU Genetically modified immune cells expressing a chimeric antigen receptor and having reduced proinflammatory cytokine signaling
CN111548420B (zh) * 2020-05-14 2021-10-15 深圳普瑞金生物药业有限公司 一种抗间皮素嵌合抗原受体、表达基因、表达载体、t细胞及其用途
WO2022098756A1 (en) * 2020-11-03 2022-05-12 WUGEN, Inc. Chimeric antigen receptor cell therapy
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN112876535B (zh) * 2021-02-08 2023-06-30 浙江华缔药业集团医药开发有限公司 生物活性多肽及其应用
WO2023025208A1 (zh) * 2021-08-24 2023-03-02 赛斯尔擎生物技术（上海）有限公司 一种修饰细胞的方法
WO2023225249A1 (en) * 2022-05-20 2023-11-23 President And Fellows Of Harvard College Methods and compositions relating to treatment of cns diseases
EP4604967A1 (en) * 2022-10-20 2025-08-27 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy
KR20250089538A (ko) * 2022-10-20 2025-06-18 마이크로크리스퍼 피브이티 리미티드 면역치료에서의 사이토카인 방출 증후군 감소
CN120098126A (zh) * 2023-02-22 2025-06-06 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
WO2025077790A1 (en) * 2023-10-11 2025-04-17 Chengdu Ucello Biotechnology Co., Limited Engineered immune cells and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
US20170334964A1 (en) * 2014-02-27 2017-11-23 Ucl Business Plc Ligand
US20180008638A1 (en) * 2015-02-06 2018-01-11 National University Of Singapore Methods for Enhancing Efficacy of Therapeutic Immune Cells
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
WO2018068354A1 (zh) * 2016-10-11 2018-04-19 上海优卡迪生物医药科技有限公司 人源白细胞介素 6 的 siRNA 、重组表达 CAR-T 载体及其构建方法和应用
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2872171T (lt) 2012-07-13 2021-04-26 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo reguliavimas
US10494434B2 (en) 2013-12-20 2019-12-03 Fred Hutchinson Cancer Research Center Tagged chimeric effector molecules and receptors thereof
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2017112877A1 (en) 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Chimeric antigen receptors and enhancement of anti-tumor activity
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3494132A4 (en) 2016-08-03 2020-03-18 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
CA3048648A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation T cells expressing a chimeric antigen receptor
US11673962B2 (en) * 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
WO2019076486A1 (en) 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY
WO2019099993A1 (en) 2017-11-17 2019-05-23 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating cytokine release syndrome
JP2021525530A (ja) 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
US20170334964A1 (en) * 2014-02-27 2017-11-23 Ucl Business Plc Ligand
US20180008638A1 (en) * 2015-02-06 2018-01-11 National University Of Singapore Methods for Enhancing Efficacy of Therapeutic Immune Cells
WO2017180989A2 (en) * 2016-04-15 2017-10-19 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
WO2018068354A1 (zh) * 2016-10-11 2018-04-19 上海优卡迪生物医药科技有限公司 人源白细胞介素 6 的 siRNA 、重组表达 CAR-T 载体及其构建方法和应用
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDRAS HECZEY 等: "Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy", 《BLOOD》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735558A (zh) * 2018-12-12 2019-05-10 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
CN114410686A (zh) * 2021-12-24 2022-04-29 武汉大学 一种工程化外泌体原位纳米疫苗及其制备方法和应用
CN114410686B (zh) * 2021-12-24 2023-10-03 武汉大学 一种工程化外泌体原位纳米疫苗及其制备方法和应用
CN116102662A (zh) * 2022-10-10 2023-05-12 武汉波睿达生物科技有限公司 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用
CN116240173A (zh) * 2023-02-02 2023-06-09 西安电子科技大学 一种冷热肿瘤调控型car-单核/巨噬细胞及其制备方法和应用
CN117186202A (zh) * 2023-11-08 2023-12-08 北京大学第三医院（北京大学第三临床医学院） 一种新细胞因子csbf及其在干眼治疗中的应用
CN117186202B (zh) * 2023-11-08 2024-02-02 北京大学第三医院（北京大学第三临床医学院） 一种新细胞因子csbf及其在干眼治疗中的应用
CN117866110A (zh) * 2023-12-27 2024-04-12 广东唯泰生物科技有限公司 一种靶向flt-3的第四代嵌合抗原受体及其应用
CN117866110B (zh) * 2023-12-27 2024-06-11 广东唯泰生物科技有限公司 一种靶向flt-3的第四代嵌合抗原受体及其应用
CN119345372A (zh) * 2024-10-28 2025-01-24 北京大学人民医院 Cd132在治疗aml中的应用

Also Published As

Publication number Publication date
EP3802578A1 (en) 2021-04-14
EP3802578A4 (en) 2022-03-23
US12304941B2 (en) 2025-05-20
WO2019232425A1 (en) 2019-12-05
JP2021525530A (ja) 2021-09-27
US20200054675A1 (en) 2020-02-20
US20230074186A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
CN112533942A (zh) 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
JP7300763B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP7542854B2 (ja) がんを治療するためのキメラ抗原受容体ｔ細胞（ｃａｒ－ｔ）
US20240307451A1 (en) Immunocompetent cell and expression vector expressing regulatory factors of immune function, and chimeric antigen receptor
CN112584844A (zh) 用于治疗血液系统恶性肿瘤的基因组编辑的恒定自然杀伤t(inkt)细胞
CN112867498A (zh) 使用嵌合抗原受体基因组编辑和转导t细胞以用于治疗t和b细胞恶性肿瘤的方法
JP7233720B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
JP7436056B2 (ja) がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品
WO2019057102A1 (en) HPK1 TARGETING ARNG AND HPK1 GENE EDITING METHOD
US20230036065A1 (en) Methods for cancer immunotherapy
CN119998322A (zh) 基因编辑靶基因以增强自然杀伤细胞功能
JPWO2019177151A1 (ja) 遺伝子改変細胞及びその作製方法
US20220411479A1 (en) Cd20 chimeric antigen receptors and methods of use for immunotherapy
JP2023537104A (ja) シグレック６結合ポリペプチド
US20250009800A1 (en) Methods for cancer immunotherapy
US20230190780A1 (en) Methods for immunotherapy
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12
WO2020154889A1 (zh) 具有Fc突变体的抗体与效应细胞的组合、用途和制法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210319